Tectonic Therapeutic (TECX) vs Valneva (VALN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Tectonic Therapeutic (TECX) has outperformed Valneva (VALN) over the past year, gaining 52.3% versus a loss of 44.9%. Over five years, TECX leads with a -67.4% price change compared with -79.1% for VALN. Valneva is the larger company by market cap ($556.6 million vs $444.0 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TECX | VALN |
|---|---|---|
| Share price | $22.71 | $5.87 |
| Market cap | $443.97M | $556.61M |
| 1-day change | +1.34% | +0.17% |
| YTD return | +8.87% | -33.45% |
| 1-year return | +52.31% | -44.88% |
| 5-year return | -67.37% | -79.07% |
| Forward P/E | — | 4.93 |
| EPS (TTM) | $-4.63 | $-2.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $39.53 | $12.18 |
| 52-week low | $15.32 | $4.75 |
| Distance from 52-week high | -42.55% | -51.81% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +237.43% | +108.69% |
| Average volume | 219.12K | 77.94K |
| Shares outstanding | 19.55M | 94.82M |
| Employees | 60 | 620 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TECX has outperformed VALN by 97.2 percentage points over the past year.
About Tectonic Therapeutic
TECX stock →Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines.
Healthcare · Biotechnology · 60 employees
About Valneva
VALN stock →Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus.
Healthcare · Biotechnology · 620 employees
TECX vs VALN FAQ
Which is bigger, Tectonic Therapeutic or Valneva?
Valneva (VALN) is larger, with a market capitalization of $556.61M compared with $443.97M for Tectonic Therapeutic (TECX).
Which stock has performed better over the past year, TECX or VALN?
TECX returned +52.31% over the past 12 months, compared with -44.88% for VALN (price return, excluding dividends). Past performance does not predict future results.
Are Tectonic Therapeutic and Valneva in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.